chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This is a cluster of 2 unidentified patients who experienced similar adverse events following vaccination with ADACEL. Initial report received from a health care professional on 06 July 2011. A group of 2 unidentified patients, with a history of allergies to seafood, received an injection (route and site not reported) of ADACEL, Sanofi Pasteur lot number not reported, on an unknown date. The patient's had mild to moderate reactions. The outcome was not reported. Documents held by sender: None
Fever of 100; chills; headache; Other Vaccine on Same date product: Flu shot (Influenza vaccine); This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 19Oct2022 at 17:15 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 41 years intramuscular, in left arm for covid-19 immunisation; influenza vaccine (FLU [INFLUENZA VACCINE]), on 19Oct2022 as dose number unknown, single (Batch/Lot number: unknown), in left arm for immunisation. The patient's relevant medical history included: "If COVID prior vaccination: Yes" (unspecified if ongoing), notes: If COVID prior vaccination: Yes. Concomitant medication(s) included: ATORVASTATIN. Vaccination history included: Covid-19 vaccine (Dose:3, MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (Dose:2, MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (Dose:1, MANUFACTURER UNKNOWN), for COVID-19 Immunization. The following information was reported: PRODUCT USE ISSUE (non-serious) with onset 19Oct2022, outcome "unknown", described as "Other Vaccine on Same date product: Flu shot (Influenza vaccine)"; PYREXIA (non-serious) with onset 20Oct2022 at 07:00, outcome "recovering", described as "Fever of 100"; CHILLS (non-serious) with onset 20Oct2022 at 07:00, outcome "recovering"; HEADACHE (non-serious) with onset 20Oct2022 at 07:00, outcome "recovering". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of pyrexia, chills, headache.  Additional information: The patient had no known allergies. The patient did not receive other vaccine in four weeks. The patient was not tested for COVID post vaccination.   The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
seven days after receiving the shot I developed a rash and ichy sensation around the injection site.  On the day of the vaccination I thought my tongue was a little swollen.
Physician called to report an adverse reaction to the COVID-19 vaccine.  Patient  had a 6.5 cm x 6.5 cm reaction at her injection site.   This included erythema, warmth, and swelling.    The patient also reported chills.    Patient's O2 saturation measured at 80% a few hours after the vaccination.   Patient received a liter of oxygen on Saturday and Sunday.    Patient was tested for COVID-19 and had a negative result.    On Monday and Tuesday, patient was given 25mg of oral diphenhydramine as the injection site had not improved.     Patient has a mild history of asthma, but is not currently taking any medications for that condition.
tremors, involuntary jerking, generalized weakness, confusion, had diarrhea 2 days prior. Provider stopped Bumex, and spironolactone  and encouraged fluids. evaluation continuing
death; This is a spontaneous report from a consumer. A 39 years old male patient (brother in law, sister's husband) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 05May2021 (Batch/Lot number was not reported) as 2nd dose, Single for covid-19 immunisation. The patient medical history and concomitant medications were not reported.  The patient experienced death on 06May2021. He received his second pfizer vaccination shot less than 24 hours before his death. Official cause of death hasn't been determined. He simply never woke up the next day and reporter's sister found him cold and blue in their bedroom. The patient died on 06May2021. An autopsy was performed and results were not provided.  Information on the lot/batch number has been requested.; Reported Cause(s) of Death: unknown cause of death
"Feeling itchy all over" and reports rash in arm pits and on legs. Sent her to hospital ER. She also reported her skin was red all over. IV med given and discharged with Prednisone and Benadryl x 3 days.
Pain, swollen arm, huge lump at site of vaccine. Redness from shoulder to wrist. Confusion, inability to think, feelings of coldness. A sense that I might die.  Neurological lack of coordination. Can't speak properly.
Woke up 4/23/21 day after 2nd dose of COVID vaccine in early morning with totally debilitating migraine headache. Was unable to do anything that day except sit on a chair.  Since that date the headache has subsided some but has never gone away. On the scale of 1-10 daily pain fluctuates between 3-10. I have not had a headache free day since receiving my 2nd shot. I waited a few months before going to my doctor hoping it would go away over a few months. In September I couldn't take the daily pain any longer and wen to my doctor, still don't know why I still have the headaches and still no relief.
Per the County Medical Examiner's Office, "This 60-year-old male with chronic ethanolism and recent 1st dose COVID-19 vaccination was witnessed to collapse on the commode at home. Cause of death is pulmonary thromboembolism due to deep vein thrombosis. Hypertensive and atherosclerotic cardiovascular disease, ethanolism and recent COVID-19 vaccination are contributory conditions. The manner of death is natural."
At first, I thought it was a sinus infection, I was going in to get antibiotics. The doctor suggested I get tested for COVID-19, influenza a and b, RSV. The office called me on the way home to let me know, I was positive. I had a low-grade fever, chills, body aches. After three days the symptoms were gone but I still tested positive for another eight days. I am now feeling much better,
I had the first vaccine 12/29/20 Pfizer EL0140, second vaccine 1/22/2021 EL3246 The first signs appeared the first part of June, extensice inflammation, unable to walk.
Injection given 8/23/18. Pt was uncooperative and was poked 2x. Vaccine was diluted with 2ml sterile water, then 0.3ml was administered percutaneously. Site was initially swollen and red, then improved. Around 9/10/18 site started getting red - increased over 1x, marginally increased 9/16/18-9/17/18. 4cm area of induration with 2.5cm X 2.7cm central area of inflammation with central area of ulceration 1cm X 1.3cm. No fever. Treatment- none, watch and wait, anticipated it will improve over the next couple months.
Renal function abnormalities identified during standard blood work in late January 2023, diagnosed with multiple myeloma in February 2023. No direct indication this was related to the Pfizer-BioNTech bivalent shot or earlier Covid19 vaccines. Reporting this per V-Safe guidance.
4th HIB shot cause severe allergic reaction. Causing baseball sized swelling at site of shot. Mass was very red, hot to the touch, and extremely painful for baby. He was up crying all night, had slight fever. Caused a red patchy rash to appear on abdomen last in a week.
tongue swelling, tongue numbness, shortness of breath, fatigue, weakness, rhinorrhea
Telephone call from mother: reports client developed fever, stomach cramps and vomiting at about 5 pm yesterday. States has been giving him Tylenol as instructed. Does not have thermometer, but "think" temp is around 100 degrees.
Pt recv vax on 10/22/98; on 10/23/98 pt exp fever (102.6), erythematous area of Lt leg w/ induration & erythema left eye; tx=Cephalexin suspension., Tylenol & Advil
This case was reported by a pharmacist via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 76-year-old female patient who received SHINGRIX (batch number H547E, expiry date 22nd February 2021) for prophylaxis. On 9th November 2018, the patient received the 1st dose of SHINGRIX. On 10th November 2018, 1 days after receiving SHINGRIX, the patient experienced extensive swelling of vaccinated limb and injection site erythema. On an unknown date, the outcome of the extensive swelling of vaccinated limb and injection site erythema were recovered/resolved. It was unknown if the reporter considered the extensive swelling of vaccinated limb and injection site erythema to be related to SHINGRIX. Additional details were provided as follows: The patient experienced an area of swelling and redness from the injection site to the elbow. These symptoms persisted for 2 and half to 3 weeks and resolved. The reporter consented to follow up.
pt recv vax & devel an inj site rxn characterized by a 2.5in area of swelling, induration & erythema;pt treated w/warm soaks & APAP;This is 1 of 6 reports from this facility of inj site rxn p/vax;
Immunizations were given in error to the wrong student. The student who received the immunizations had a complete immunization record for school prior to these vaccines being administered.
This spontaneous report as received from a physician refers to a 79 year old male patient. No pertinent history was reported. On 04-MAY-2007, the patient was vaccinated with ZOSTAVAX Lot # 656395/0190U (Expiry: 02-AUG-2008) (dose, route and frequency were not reported). No concomitant medications were reported. On 18-FEB-2014, the patient experienced shingles. The patient sought medical attention and visited the office and was treated with unspecified antiviral medication. No lab diagnostics studies performed. The outcome of the event shingles was reported as recovering. The reporter did not provide the causality between the event and the suspect drug. Additional information has been requested.
Twinrix 1st dose on 19-Jan-2022, came to get 2nd dose today (11-Aug-2022) not get yet.; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 58-year-old male patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (1st dose received on 19 January 2022 from lot number X239D and expiry date 7th August 2022).   On an unknown date, the patient received the 2nd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 11-AUG-2022 Reporter's Comment: The reporter was a pharmacist. The reporter reported that the patient received 1st dose of Twinrix Vaccine. The reporter stated that the patient was back for the second dose today (on the day of reporting). The reporter stated that the patient did not received the 2nd dose on 11th August 2022. The reporter asked the if patient should receive second dose or restart the series. The reporter consented to follow up.  Additional supportive information: Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination.
Has not had a desire to eat; Couldn't touch behind her right side of her ear; Experienced joint pain; Developed a mild headache; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE (Has not had a desire to eat), EAR DISCOMFORT (Couldn't touch behind her right side of her ear), HEADACHE (Developed a mild headache) and ARTHRALGIA (Experienced joint pain) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Dec-2020, the patient experienced HEADACHE (Developed a mild headache). On 01-Jan-2021, the patient experienced ARTHRALGIA (Experienced joint pain). On 02-Jan-2021, the patient experienced DECREASED APPETITE (Has not had a desire to eat) and EAR DISCOMFORT (Couldn't touch behind her right side of her ear). On 02-Jan-2021, ARTHRALGIA (Experienced joint pain) had resolved. At the time of the report, DECREASED APPETITE (Has not had a desire to eat), EAR DISCOMFORT (Couldn't touch behind her right side of her ear) and HEADACHE (Developed a mild headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Treatment for the event included paracetamol, sinade, neck stretcher, epson salt bath, steroid prednisolone and erythromycin.; Sender's Comments: Very limited information regarding this events has been provided at this time. Further information has been requested. Company assessed the events to be unlikely related to company product.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 23-OCT-2012, the patient was inoculated with the ZOSTAVAX vaccine as recommended for routine adult health maintenance for the long term prevention of shingles (dose, route, and lot number not provided). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain of herpes zoster or shingles. On or about 08-OCT-2015, the patient was treated by a physician for the onset of severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
More than 36 days after the first dose without receiving the second dose; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 36 days after the first dose without receiving the second dose) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026-A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 36 days after the first dose without receiving the second dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 36 days after the first dose without receiving the second dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
pt did not achieve acceptable titer level p/3rd dose of Hep B vax;
Narrative:  A 74yo male with PMH of Alzehimer's Disease, BPH without outflow obstruction and Hypothyroidism He received his Pfizer Covid- 19 vaccine doses per policy and protocol. First dose on February 27, 2021 and the second dose on March 20,2021 without complications No Adverse Events were reported On march 24, 2021 the patient presented to the ED with wife who communicated a CC of" patient being unable to urinate x 4 days" ED - urinalysis showed no acute UTI, urine culture was sent (pending result) The patient was discharged with primary and Urology f/u Per advice line documentation on March 26, 2021, the physician documented communicating with the patient's wife regarding lab results for UA, CBC, Chem-7, TFT, mineral panel, B12 and Vitamin D, which were all unremarkable. He advised the wife to increase the patient's oral intake of fluid, to avoid dehydration, tamsulosin dose for BPH was increased to 0.8mg and fenasteride was added. Nutrition education and f/u were in place. April 2, 2021 vascular imaging indicated occlusion of LT internal carotid artery. On April 12, 2021 the patient again presented to the ED with wife w/CC of" not able to eat x 4 days and failure to thrive" and was admitted. The system showed this patient passed away on April 28, 2021
muscles in arm began to tighten; bruising  arm extending from my shoulder to my elbow; bumps and puffiness on my arm extending from my shoulder to my elbow; tenderness at the site of the vaccine; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old-non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8730) via unspecified route of administration on 26Mar2021 at 12:30 (at the age of 32-years-old) as a single dose for Covid-19 immunisation. The patient's medical history included asthma. Concomitant medication included ibuprofen (MANUFACTURER UNKNOWN) for unknown indication on 26Mar2021(2 hours prior the vaccination). The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  On 26Mar2021, the patient experienced tenderness at the site of the vaccine, within a few hours muscles in arm began to tighten then began to see bruising, bumps and puffiness on arm extending from shoulder to elbow. These bumps and puffiness lasted for about a week. No therapeutic measures were taken as a result of the reported events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the tenderness at the site of the vaccine, muscle tightness, bruising on arm extending from shoulder to elbow was recovering and bumps and puffiness on arm extending from shoulder to elbow was recovered on an unknown date.    No follow-up attempts are needed. No further information is expected.
PATIENT WAS 16 YEARS OLD WHEN HE RECEIVED THE MODERNA VACCINE. ON 04/17/2021, UPON REALIZATION OF THE UNDER AGE ADMINISTRATION,  I CONTACTED THE PARENTS WHO STATED THAT PATIENT WAS  FINE AND WITH OUT INCIDENT. HE IS A BIG GUY AND TOLERATED THE VACCINE WELL. I ADVISED THEM TO FOLLOW UP WITH PRIMARY CARE AND I WOULD HAVE TO REPORT THIS EVENT AND SEEK FURTHER GUIDANCE REGARDING SECOND DOSE ADMINISTRATION.
VACCINE ADMINISTERED OUTSIDE OF EAU PATIENT HAD MILD FLU-LIKE SYMPTOMS AFTER ADMINISTRATION
Reports day after horrible headache, reoccuring of headache last ten days. Right side abdominal discomfort, joint and muscle aches. Taking Ibuprofen everyday one to two times a day. Fatigue no fever.
Felt like she had the flu; pain in arm; headache; A spontaneous report was received from a consumer concerning a 69-year-old, female patient who developed pain in arm/ pain in extremity, headache and felt like she had the flu/ influenza like illness.   The patient's medical history was not provided. Concomitant product use was not provided by the reporter.      On 14 Jan 2021, patient received first dose of vaccine and experienced events, pain in arm/ pain in extremity, headache and felt like she had the flu/ influenza like illness.     Treatment information was not provided.    Action taken with mRNA-1273 in response to the events was not provided.  The outcome of the events was not reported.
Chills low-grade fever nausea vomiting headacheLasting for 24 hours
Headache, Myalgia, Arthralgia, Fever, X 2 DAYS Narrative:
Desquamating red skim, central area of scab. Not redness that is spreading too much, warm, tender, most likely inflammation, worsened from 2-6 days after the shot.
Developed Heart Rhythm issues and PVC beats; Developed Heart Rhythm issues and PVC beats; other vaccine same date as vaccine date; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old male patient received BNT162b2 (BNT162B2), on 27Oct2021 at 09:30 as dose 3 (booster), single (Lot number: PF2080) at the age of 62 years, in right arm for covid-19 immunisation; influenza vaccine (INFLUENZA), on 27Oct2021 as dose 1, single (Batch/Lot number: unknown), in left arm for immunisation. The patient's relevant medical history included: "A-Fib" (unspecified if ongoing). The patient took concomitant medications. Past drug history included: Atorvastatin, reaction(s): "Known allergies: Atorvastatin". Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: LR 8727, Location of injection: Arm Right, Vaccine Administration Time: 09:00 AM), administration date: 27Mar2021, when the patient was 62-year-old, for Covid-19 immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion, Location of injection: Arm Right, Vaccine Administration Time: 01:00 PM), administration date: 06Mar2021, when the patient was 62-year-old, for Covid-19 immunization. The following information was reported: ARRHYTHMIA (disability, medically significant, life threatening), VENTRICULAR EXTRASYSTOLES (disability, life threatening) all with onset 27Oct2021 at 09:30, outcome "not recovered" and all described as "Developed Heart Rhythm issues and PVC beats"; PRODUCT USE ISSUE (non-serious) with onset 27Oct2021 at 09:30, outcome "unknown", described as "other vaccine same date as vaccine date". The events "developed heart rhythm issues and pvc beats" and "other vaccine same date as vaccine date" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results. Therapeutic measures were taken as a result of arrhythmia, ventricular extrasystoles, product use issue.  Clinical information: ae treatment Cardioversion and medication. Patient was not covid prior vaccination.
Narrative: COVID infection following COVID vaccine series 02/15, Moderna , dose #1 03/16, Moderna, dose #2 10/28, dose #3 09/30 COVID swab, result: detected 09/27 pt cc: cough, fatigue, headache, myalgias, rhinorrhea, dyspnea exposure: unknown clinically resolved